Elevar Therapeutics Announces Positive Pre-NDA Meeting for Rivoceranib Combination With Camrelizumab as Hepatocellular Carcinoma Treatment Option
11 oct. 2022 16h00 HE
|
Elevar Therapeutics
SALT LAKE CITY, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
Liver Cancer Diagnostics Market Worth $15.95Bn, Globally, by 2028 at 8% CAGR - Exclusive Report by The Insight Partners
07 avr. 2022 10h50 HE
|
The Insight Partners
New York, April 07, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Liver Cancer Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type...
Celsion Corporation Reports Third Quarter 2020 Financial Results and Provides Business Update
16 nov. 2020 08h30 HE
|
Celsion CORP
Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer Continues Following Patients for Overall Survival in Phase III OPTIMA Study Conference Call Begins Today at 11:00...
Celsion Corporation Issues Letter to Stockholders
12 oct. 2020 08h00 HE
|
Celsion CORP
CEO Provides Updates on Phase III OPTIMA Study Data Analysis and ThermoDox® Investigator-Sponsored Studies LAWRENCEVILLE, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:...
Provectus Biopharmaceuticals Highlights Stage IV M1c Patient Outcome from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020
21 sept. 2020 12h45 HE
|
Provectus Biopharmaceuticals Inc.
Near-resolution of tumor burden, including extensive visceral hepatic diseaseExpanded data set of trial subject provided KNOXVILLE, TN, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT)...
Celsion Corporation Receives Recommendation from Independent Data Monitoring Committee to Consider Stopping the Phase III OPTIMA Study
13 juil. 2020 08h30 HE
|
Celsion CORP
Recommendation Based on DMC’s Finding Following the Second Pre-Planned Interim Analysis that the OPTIMA Study is Unlikely to Meet its Primary Efficacy Endpoint of Overall Survival Celsion...
Celsion Affirms July Timing for Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
25 juin 2020 08h00 HE
|
Celsion CORP
LAWRENCEVILLE, N.J, June 25, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, today affirmed that the independent Data Monitoring Committee (iDMC)...
Celsion Corporation Reports First Quarter 2020 Financial Results and Provides Business Update
15 mai 2020 08h00 HE
|
Celsion CORP
Phase III OPTIMA Study on Track for Interim Data Analysis in July Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J, May 15, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation...
首个抗肿瘤候选植物药“YIV-906”与索拉非尼联合治疗肝细胞癌的IIb期临床试验正式启动
06 avr. 2020 07h00 HE
|
Yiviva
—— 利用整合系统生物学方法，由耶鲁大学郑永齐教授和医起共同开发的首个抗肿瘤候选植物药 中国上海，美国纽约, April 06, 2020 (GLOBE NEWSWIRE) -- 生物制药创新企业医起医药科技有限公司（Yiviva Inc.），在2020年初正式启动了YIV-906联合索拉非尼治疗乙型肝炎相关性肝细胞癌（HCC）的一线疗法IIb期研究，并于今年三月迎来了第一位受试者。 ...
Yiviva Announces Dosing of First Patient in Phase 2b Study of First-Line YIV-906 Plus Sorafenib Combination Therapy in the Treatment of Hepatocellular Carcinoma
06 avr. 2020 07h00 HE
|
Yiviva
- First-in-class oncology therapeutic candidate YIV-906 applies an integrative systems biology approach -- Global study to evaluate efficacy, safety, and quality of life in patients with hepatitis...